PDAB wants to hear from Oregonians about prescription drug costs
Share your experience by submitting a feedback form
The Oregon Prescription Drug Affordability Board (PDAB) is seeking input from patients, caregivers, and other Oregonians about the cost of prescription medications and how those costs affect daily lives. The board invites patients, caregivers, advocacy groups, medical professionals, manufacturers, safety net clinics, pharmacy benefit managers, and health plan insurers to submit a feedback form for the prescription drugs currently under review. PDAB will review the following medications to evaluate their affordability and their impact on Oregonians and the state’s health care system:
Jardiance, Mounjaro, Ozempic, Humulin R U-500, Keytruda, Verzenio, Xeljanz, Ocrevus, Skyrizi, Tremfya, and Xolair.
If any of these medications have affected your health, finances, or the communities you serve, we encourage you to share your experiences with the board. Your feedback will help inform PDAB’s review process. Click on the link below to select the applicable form, complete the questions, and submit the form. The category descriptions will help you determine which form to use. Thank you, in advance, for your participation.
2026 feedback forms
-
Patients, caregivers, and advocacy
For individuals who have been prescribed a medication on the review list, as well as their caregivers or family members. Advocacy groups representing patients or caregivers may also choose this form.
-
Individuals with scientific or medical training
For medical providers, doctors, nurses, professors, researchers, pharmacists, representatives of medical clinics and hospitals, and others with a background and training in medicine or science.
-
Safety net provider
For 340B clinics, federally qualified health centers serving Oregon communities, and coordinated care organizations serving Oregon Health Plan members.
-
Manufacturer
For companies that manufacture prescription drugs and trade associations representing manufacturers.
-
Pharmacy benefit manager
For pharmacy benefit managers – third-party administrators that manage prescription drug programs for health plans.
-
Health plan insurer
For companies that provide health insurance to Oregonians.
El PDAB quiere escuchar a los habitantes de Oregón sobre los costos de los medicamentos recetados.
Comparta su experiencia enviando un formulario de comentarios.
La Junta de Asequibilidad de Medicamentos Recetados de Oregón (PDAB) solicita la opinión de pacientes, cuidadores y otros habitantes de Oregón sobre el costo de los medicamentos recetados y cómo dichos costos afectan su vida cotidiana. La junta invita a pacientes, cuidadores, grupos de defensa, profesionales médicos, fabricantes, clínicas de la red de seguridad, gestores de beneficios farmacéuticos y aseguradoras de planes de salud a enviar un formulario de comentarios sobre los medicamentos recetados que se encuentran actualmente bajo revisión. PDAB revisará los siguientes medicamentos para evaluar su asequibilidad y su impacto en los habitantes de Oregón y en el sistema de atención médica del estado:
Jardiance, Mounjaro, Ozempic, Humulin R U-500, Keytruda, Verzenio, Xeljanz, Ocrevus, Skyrizi, Tremfya, and Xolair.
Si alguno de estos medicamentos ha afectado su salud, sus finanzas o las comunidades a las que presta servicio, le invitamos a compartir sus experiencias con la junta. Sus comentarios ayudarán a orientar el proceso de revisión del PDAB. Por favor, Haga clic en el enlace de abajo para seleccionar el formulario, responder las preguntas y enviarlo. Muchas gracias.
Formulario de retroalimentación 2026 en español